• Reliance Global Group launched LifeSci Global, a dedicated life sciences and biotechnology platform, anchored by a strategic investment in Innervate Radiopharmaceuticals as its first platform transaction.
• Innervate develops PET imaging and a therapeutic program initially focused on neuroblastoma, with Reliance citing an estimated $250 million market opportunity for the initial indication.
• Scott Korman was named founding operator-partner for LifeSci Global while serving as Innervate chief executive and a Reliance board member; David Turner will serve as the platform’s other founding operator-partner while acting as Innervate chief operating officer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Reliance Global Group Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605050925PRIMZONEFULLFEED9713307) on May 05, 2026, and is solely responsible for the information contained therein.